We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Xenoport, Inc. | NASDAQ:XNPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.07 | 7.03 | 7.06 | 0 | 01:00:00 |
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
¨ | Preliminary Proxy Statement | |
¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
¨ | Definitive Proxy Statement | |
x | Definitive Additional Materials | |
¨ | Soliciting Material Pursuant to §240.14a-12 |
XenoPort, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
NEWS RELEASE | Company Contact: | |||
For Immediate Distribution | Jackie Cossmon | |||
408-616-7220 | ||||
ir@XenoPort.com |
XenoPort Urges Stockholders to Vote FOR ALL XenoPort Director Nominees on the WHITE Proxy Card
SANTA CLARA, Calif.June 6, 2014 XenoPort, Inc. (Nasdaq: XNPT) today reminded stockholders to vote at the Companys upcoming Annual Meeting of Stockholders on June 11, 2014.
Time is short and stockholders are encouraged to vote the WHITE proxy card today . XenoPort urges stockholders not to return any proxy card sent to them by Clinton Relational Opportunity Master Fund, L.P. and its affiliates (Clinton). Even if stockholders have already voted using the gold proxy card, they have the right to change their vote simply by executing and submitting the WHITE proxy card in support of XenoPorts director nominees. Only the last-dated proxy card will count.
Stockholders can vote by telephone or Internet according to the instructions on the WHITE proxy card. Voting by telephone or Internet is the best way to ensure that votes will be counted.
Two independent proxy advisory firms, Institutional Shareholder Services (ISS) and Egan-Jones Proxy Services (Egan-Jones), have recommended that XenoPort stockholders vote on the WHITE proxy card FOR ALL of XenoPorts director nominees : Ronald W. Barrett, Ph.D., Jeryl L. Hilleman and Wendell Wierenga, Ph.D.
XenoPort also urges stockholders to vote FOR the approval of the XenoPort, Inc. 2014 Equity Incentive Plan, vote FOR the approval, on an advisory basis, of the compensation of XenoPorts named executive officers, and vote FOR the ratification of the selection by the audit committee of the Board of Directors of Ernst & Young LLP as XenoPorts independent registered public accounting firm for the fiscal year ending December 31, 2014. In addition, the XenoPort Board urges stockholders to vote FOR Proposals 9 through 14 and AGAINST Clinton Proposals 5 through 8.
If you have any questions, require assistance with voting your WHITE
proxy card or need additional copies of the proxy materials, please contact:
105 Madison Avenue
New York, NY 10016
proxy@mackenziepartners.com
(212) 929-5500 (Call Collect)
Or
TOLL-FREE (800) 322-2885
Important Additional Information and Where to Find It
XenoPort, Inc., its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with XenoPorts 2014 Annual Meeting of Stockholders. XenoPort has filed with the SEC and provided to its stockholders a definitive proxy statement and a WHITE proxy card in connection with such solicitation. XENOPORT STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS) AND THE ACCOMPANYING WHITE PROXY CARD, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN IMPORTANT INFORMATION.
Information regarding the names of XenoPorts directors and executive officers and their respective interests in XenoPort by security holdings or otherwise is set forth in XenoPorts definitive proxy statement for the 2014 Annual Meeting of Stockholders, filed with the SEC on April 22, 2014, including Appendix B thereto.
The definitive proxy statement (and amendments or supplements thereto) and the accompanying WHITE proxy card, and any other relevant documents and other material filed by XenoPort with the SEC, are or will be available for no charge at the SECs website at www.sec.gov and at XenoPorts investor relations website at http://investor.xenoport.com/index.cfm . Copies may also be obtained free of charge by contacting XenoPort Investor Relations by mail at 3410 Central Expressway, Santa Clara, California 95051 or by telephone at (408) 616-7200.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis. REGNITE ® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPorts pipeline of product candidates also includes a potential treatment for patients with Parkinsons disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com .
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.
XNPT2G
1 Year Xenoport, Inc. Chart |
1 Month Xenoport, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions